What is claimed is:

CLAIMS

- 1. An isolated enriched or purified nucleic acid molecule encoding a PTP05 or a PTP10 polypeptide.
- 2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleotide sequence that
- (a) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8;
- (b) is the complement of the nucleotide sequence of (a);
- (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally 15 occurring PTP05 or RTP10 polypeptide;
 - (d) encodes a PTP05 or PTP10 polypeptide having the full length amino acid sequence of the sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8, except that it lacks one or more of the following segments of amino acid residues: 1-187, 188-420, 421-426 of SEQ ID NO:5, 44-80, 225-457, 458-463 of SEQ ID NO:6, or 1-87, 188-405, 406-412 of SEQ ID NO:7;
 - (e) is the complement $\oint f$ the nucleotide sequence of (d);

- (f) encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8 from amino acid residues 1-187, 188-420, 421-426 of SEQ ID NO:5, 44-80, 225-457, 458-463 of SEQ ID NO:6, or 1-87, 188-405, 406-412 of SEQ ID NO:7;
- (g) is the complement of the nucleotide sequence
 of (f);

encodes a polypeptide having the full length

amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6,

SEQ ID NO:7, or SEQ ID NO:8, except that it lacks one or

more of the domains selected from the group consisting of a

N-terminal domain, a catalytic domain, and a C-terminal

domain; or

(h)

- (i) is the complement of the nucleotide sequence 15 of (h).
 - 3. The nucleic acid molecule of claim 2, wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.
- 4. The nucleic acid molecule of claim 3, wherein 20 said mammal is a human.
 - 5. The nucleic acid molecule of claim 1, further comprising a vector or promoter effective to initiate transcription in a host cell.

a

15

- 6. A nucleic acid probe for the detection of nucleic acid encoding a PTP05 or a PTP10 polypeptide in a sample.
- 7. The probe of claim 6 wherein said polypeptide comprises at least 6 contiguous amino acids of the amino acid sequence shown in SEQ II NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.
- 8. A nucleic acid molecule comprising one or more regions that encode a PTP05 or a PTP10 polypeptide or a PTP05 or a PTP10 domain polypeptide, wherein said PTP05 or PTP10 polypeptide or said PTP05 or PTP10 domain polypeptide is fused to a non-PTP05 or non-PTP10 polypeptide.

9. A recombinant cell comprising a nucleic acid molecule encoding either

- (a) a PTP05 or a PTP10 polypeptide;
- (b) a PTP05 or a PTP10 domain polypeptide; or
- (c) a PTP05 or a PTP10 polypeptide or PTP05 or PTP10 domain polypeptide fused to a non-PTP04 polypeptide.
- 10. An isolated, enriched or purified PTP05 or PTP10 polypeptide.
- 20 11. The polypeptide of claim 10, wherein said polypeptide is a fragment of the protein encoded by the

full length amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

- 12. The polypeptide of claim 10, wherein said polypeptide comprises an amino acid sequence having
- forth in SEQ ID NO:5 SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8;
- (b) the full length amino acid sequence of the sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8, except that it lacks one or more of the following segments of amino acid residues: 1-187, 188-420, 421-426 of SEQ ID NO:5, 44-80, 225-457, 458-463 of SEQ ID NO:6, or 1-87, 188-405, 406-412 of SEQ ID NO:7;
- (c) the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8 from amino acid residues 1-187, 188-420, 421-426 of SEQ ID NO:5, 44-80, 225-457, 458-463 of SEQ ID NO:6, or 1-87, 188-405, 406-412 of SEQ ID NO:7; or
- (d) the full length amino acid sequence set

 20 forth in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID

 NO:8 except that it lacks one or more of the domains

 selected from the group consisting of an N-terminal domain,

 a catalytic domain, and C-terminal domain.

- 13. An antibody or antibody fragment having specific binding affinity to a PTP05 or a PTP10 polypeptide or a PTP05 or a PTP10 domain polypeptide.
- 14. A hybridoma which produces an antibody having 5 specific binding affinity to a PTP05 or a PTP10 polypeptide.
 - 15. A method for identifying a substance capable of modulating PTP05 or PTP10 activity comprising the steps of:
- (a) contacting a PTP05 or a PTP10 polypeptide with a 10 test substance, and
 - (b) determining whether said substance alters the activity of said polypeptide
- 16. A method for identifying a substance capable of modulating PTP05 or PTP10 activity in a cell comprising the steps of:
 - (a) expressing a PTP05 or a PTP10 polypeptide in a cell,
 - (b) adding a test substance to said cells, and
- (c) monitoring a change in cell phenotype, cell
 proliferation, cell differentiation, PTP05 or PTP10
 catalytic activity, or the interaction between a PTP05 or a
 PTP10 polypeptide and a natural binding partner.

- 17. A method of preventing or treating an abnormal condition by administering to a patient in need of such treatment a compound that modulates the function of a PTP05 or a PTP10 polypeptide.
- 5 18. The method of claim 17, wherein said abnormal condition involves an abnormality in PTP05 or PTP10 signal transduction pathway.
 - 19. The method of claim 18, wherein said abnormal condition is cancer.
- 10 20. The method of claim 17, wherein said compound modulates the function of a PTP05 or a PTP10 polypeptide in vitro.
 - 21. A kit, comprising the compound of claim 17 and a protocol for the use of said compound.
- 15 22. The kit of claim 21, wherein said protocol is approved by the Food and Drug Administration.

MU